COVID-19：第一三共运输阿斯利康疫苗：
第一三共：
6月16日，阿斯利康在英国研发的新型冠状病毒疫苗开始发货。
用进口的原液装满容器并装满。
100 万剂通过日本政府
供应东南亚。
日本政府：
5 月获批用于阿斯利康。
“海外出货3000万次政策”公布。
第一三共生物科技：
6月15日开始发货。
这一次，我们向越南运送了 100 万件货物。
自 2021 年 3 月起，将疫苗原液装入称为小瓶的特殊容器的工作一直在进行中。
外相茂木敏充：
6月15日，日本外相茂木敏充在记者会上宣布。
“我们将向以下五个国家提供疫苗，”他说。
越南，
印度尼西亚，
泰国，
马来西亚，
菲律宾，
阿斯利康疫苗：
与美国辉瑞和Moderna产品不同的是，它可以冷藏保存并且易于处理。
另一方面，国外也有接种后很少引起血栓形成的副反应的报道。
日本经济新闻
https://www.nikkei.com/article/DGXZQOUC161SX0W1A610C2000000/
Tokyo, Japan – (June 16, 2021) –
Daiichi Sankyo Company, Limited
today announced that Daiichi Sankyo Biotech Co., Ltd., has made its shipment of VAXZEVRIATM Intramuscular Injection, a vaccine against novel coronavirus developed by AstraZeneca K.K. .
This shipment of the COVID-19 vaccine is to be provided to Southeast Asian countries and other regions through the Japanese Government.
Under the contract manufacture agreement of the COVID-19 vaccine that Daiichi Sankyo concluded with AstraZeneca in February 2021, Daiichi Sankyo Biotech has engaged in manufacturing the COVID-19 vaccine, including vial filling and packaging, since March of the same year.
The Japanese government
has announced that it will supply 30 million doses of AstraZeneca’s COVID-19 vaccine to various countries and regions through COVAX1 and through other means.
In response to this announcement, a portion of the COVID-19 vaccine to be shipped from Daiichi Sankyo is expected to be provided to countries and regions including Southeast Asian countries through the Japanese Government.
As part of efforts towards ending the global COVID-19 pandemic,
Daiichi Sankyo is striving to support regions in need of medical access through contract manufacture of the COVID-19 vaccine.
https://www.daiichisankyo.com/files/news/pressrelease/pdf/202106/20210616_E.pdf